Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
Stockhead on MSN

Alterity presents positive ATH434 phase II data at key Parkinson’s conference

Alterity presents positive phase II data for ATH434 at 2025 International Congress of Parkinson’s Disease and Movement Disorders. Alterity presents positive phase II data for ATH434 at 2025 ...
Seeking Alpha

Alterity Therapeutics Prominently Featured at the International MSA Congress

MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
BioWorld

University of California divulges new α-synuclein, amyloid-β protein and MAPT propagation inhibitors

The University of California has synthesized α-synuclein (SNCA) and/or amyloid-β protein and/or microtubule-associated protein tau (PHF-tau; MAPT) propagation inhibitors reported to be useful for ...